Partners and Investors
Partnership Collaboration and Investment Opportunities
Cend will enter partnerships to enable more effective solid tumor cancer delivery for a range of therapeutic modalities.
Cend and its collaborators have demonstrated ability to enhance delivery and antitumor activity of:
Natural killer (NK) cell therapies
Cytotoxic T lymphocytes (CTLs)
messenger RNA (mRNA)